BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29401170)

  • 1. Effect of Reprimo Down-regulation on Malignant Transformation of Intraductal Papillary Mucinous Neoplasm.
    Nakazato T; Suzuki Y; Tanaka R; Abe N; Masaki T; Mori T; Ohkura Y; Sugiyama M
    Pancreas; 2018 Mar; 47(3):291-295. PubMed ID: 29401170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fucosylation is associated with the malignant transformation of intraductal papillary mucinous neoplasms: a lectin microarray-based study.
    Watanabe K; Ohta M; Yada K; Komori Y; Iwashita Y; Kashima K; Inomata M
    Surg Today; 2016 Oct; 46(10):1217-23. PubMed ID: 26754572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas.
    Hong SM; Omura N; Vincent A; Li A; Knight S; Yu J; Hruban RH; Goggins M
    Clin Cancer Res; 2012 Feb; 18(3):700-12. PubMed ID: 22173550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
    Sato N; Ueki T; Fukushima N; Iacobuzio-Donahue CA; Yeo CJ; Cameron JL; Hruban RH; Goggins M
    Gastroenterology; 2002 Jul; 123(1):365-72. PubMed ID: 12105864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.
    Kuroki H; Hayashi H; Okabe H; Hashimoto D; Takamori H; Nakahara O; Nakagawa S; Fukushima Y; Chikamoto A; Beppu T; Hirota M; Iyama K; Baba H
    PLoS One; 2014; 9(8):e100904. PubMed ID: 25084021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms.
    Yoshida K; Nagasaka T; Umeda Y; Tanaka T; Kimura K; Taniguchi F; Fuji T; Shigeyasu K; Mori Y; Yanai H; Yagi T; Goel A; Fujiwara T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1557-69. PubMed ID: 27095449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.
    Basturk O; Chung SM; Hruban RH; Adsay NV; Askan G; Iacobuzio-Donahue C; Balci S; Zee SY; Memis B; Shia J; Klimstra DS
    Virchows Arch; 2016 Nov; 469(5):523-532. PubMed ID: 27591765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
    Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
    Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas.
    Jang JY; Park YC; Song YS; Lee SE; Hwang DW; Lim CS; Lee HE; Kim WH; Kim SW
    J Hepatobiliary Pancreat Surg; 2009; 16(5):668-74. PubMed ID: 19412570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and in vitro propagation of intraductal papillary mucinous neoplasms.
    Kamiyama H; Kamiyama M; Hong SM; Karikari CA; Lin MT; Borges MW; Griffith M; Young A; Norris-Kirby A; Lubek C; Mizuma M; Feldmann G; Shi C; Liang H; Goggins MG; Maitra A; Hruban RH; Eshleman JR
    Lab Invest; 2010 May; 90(5):665-73. PubMed ID: 20231822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
    Hashimoto Y; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Ohge H; Fukuda E; Shimamoto F; Sueda T; Hiyama E
    J Gastrointest Surg; 2008 Jan; 12(1):17-28; discussion 28-9. PubMed ID: 17960465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features.
    Omori Y; Ono Y; Tanino M; Karasaki H; Yamaguchi H; Furukawa T; Enomoto K; Ueda J; Sumi A; Katayama J; Muraki M; Taniue K; Takahashi K; Ambo Y; Shinohara T; Nishihara H; Sasajima J; Maguchi H; Mizukami Y; Okumura T; Tanaka S
    Gastroenterology; 2019 Feb; 156(3):647-661.e2. PubMed ID: 30342036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.
    Chang X; Yu C; Li J; Yu S; Chen J
    Int J Med Sci; 2017; 14(5):412-418. PubMed ID: 28539816
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
    Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
    Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.
    Ban S; Naitoh Y; Mino-Kenudson M; Sakurai T; Kuroda M; Koyama I; Lauwers GY; Shimizu M
    Am J Surg Pathol; 2006 Dec; 30(12):1561-9. PubMed ID: 17122512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.
    Sato N; Matsubayashi H; Abe T; Fukushima N; Goggins M
    Clin Cancer Res; 2005 Jul; 11(13):4681-8. PubMed ID: 16000561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical role of Notch signaling pathway in intraductal papillary mucinous neoplasm of the pancreas.
    Ikemoto T; Sugimoto K; Shimada M; Utsunomiya T; Morine Y; Imura S; Arakawa Y; Kanamoto M; Iwahashi S; Saito Y; Yamada S
    J Gastroenterol Hepatol; 2015 Jan; 30(1):217-22. PubMed ID: 25041344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.